These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38335182)

  • 1. Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review.
    Hajizadeh N; Heidari A; Sadeghi S; Goodarzi A
    PLoS One; 2024; 19(2):e0293433. PubMed ID: 38335182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review.
    Brehm TT; Reimann M; Köhler N; Lange C
    Clin Microbiol Infect; 2024 Aug; 30(8):989-998. PubMed ID: 38663653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
    Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
    Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.
    Lopetuso LR; Cuomo C; Mignini I; Gasbarrini A; Papa A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
    Smajlović H; Prohić A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
    Papierzewska M; Waśkiel-Burnat A; Rudnicka L
    Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.
    Armstrong N; Joore M; van Asselt T; Misso K; Manning N; Tomini F; Kleijnen J; Riemsma R
    Pharmacoeconomics; 2013 May; 31(5):415-25. PubMed ID: 23580355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
    Michaud TL; Rho YH; Shamliyan T; Kuntz KM; Choi HK
    Am J Med; 2014 Dec; 127(12):1208-32. PubMed ID: 24950486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
    Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
    Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M
    PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
    Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
    World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.